Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 18/20 | 0.44 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.43 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.41 |
| ▸ | F2 | P00734 | 1/20 | 0.41 |
| ▸ | ST14 | Q9Y5Y6 | 1/20 | 0.41 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | CYP2J2 | P51589 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7722222 | 1.00 | F10 (0.44) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL116674 | 1.00 | F10 (0.44) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7734355 | 0.88 | F10 (0.45) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7722210 | 0.88 | F10 (0.46) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7723601 | 0.88 | F10 (0.46) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL120142 | 0.87 | F10 (0.47) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL120141 | 0.87 | F10 (0.47) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL21278618 | 0.86 | F10 (0.46) | F10CYP1A2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL7727260 | 0.80 | F10 (0.46) | F10PTGS2 | |
| SCHEMBL7727829 | 0.80 | F10 (0.46) | F10PTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 34 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9598403-B2 | Process for the preparation of rivaroxaban | AMNEAL PHARMACEUTICALS LLC (US) | 2017-03-21 | — | — | US | disclosed |
| US-9598403-B2 | Process for the preparation of rivaroxaban | AMNEAL PHARMACEUTICALS LLC (US) | 2017-03-21 | — | — | US | disclosed |
| EP-2837628-B1 | METHOD FOR PREPARING RIVAROXABAN INTERMEDIATE | CHINA NAT MEDICINES GUORUI PHARMACEUTICAL CO LTD (CN) | 2016-11-30 | — | — | EP | disclosed |
| US-20160194309-A1 | A Process For The Preparation Of Rivaroxaban | AMNEAL PHARMACEUTICALS LLC | 2016-07-07 | — | — | US | disclosed |
| US-20160194309-A1 | A Process For The Preparation Of Rivaroxaban | AMNEAL PHARMACEUTICALS LLC | 2016-07-07 | — | — | US | disclosed |
| EP-2424847-B1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC (CA) | 2016-04-06 | — | — | EP | disclosed |
| US-9079892-B2 | Method for preparing rivaroxaban intermediate | CHINA NATIONAL MEDICINES GUORUI PHARMACEUTICAL CO., LTD. (CN) | 2015-07-14 | — | — | US | disclosed |
| US-9079892-B2 | Method for preparing rivaroxaban intermediate | CHINA NATIONAL MEDICINES GUORUI PHARMACEUTICAL CO., LTD. (CN) | 2015-07-14 | — | — | US | disclosed |
| WO-2015026761-A1 | A PROCESS FOR THE PREPARATION OF RIVAROXABAN | AMNEAL PHARMACEUTICALS LLC (US) | 2015-02-26 | — | — | WO | disclosed |
| EP-2837628-A1 | METHOD FOR PREPARING RIVAROXABAN INTERMEDIATE | China National Medicines Guorui Pharmaceutical Co., Ltd. (CN) | 2015-02-18 | — | — | EP | disclosed |
| WO-2010124385-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-11-04 | — | — | WO | disclosed |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | APOTEX PHARMACHEM INC. (CA) | 2010-10-28 | — | — | US | disclosed |
| US-7816355-B1 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX PHARMACHEM INC (CA) | 2010-10-19 | — | — | US | disclosed |
| US-7816355-B1 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX PHARMACHEM INC (CA) | 2010-10-19 | — | — | US | disclosed |
| US-7816355-B1 | Processes for the preparation of rivaroxaban and intermediates thereof | APOTEX PHARMACHEM INC (CA) | 2010-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160194309-A1 | A Process For The Preparation Of Rivaroxaban | TFPI, VKORC1, VKORC1L1 | F10 13/4885CYP1A2 17/4885CYP3A4 6/4885 |
| US-20100273798-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | CYP2C9, F2, F9 | F10 8/4885CYP1A2 18/4885CYP3A4 12/4885 |
| US-20100273790-A1 | PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF | CYP2C9, F2, F9 | F10 7/4885CYP1A2 19/4885CYP3A4 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.